Feature story |

2006: Thailand begins to issue compulsory licences

Photograph by Stefan Pleger
Surin, programme SIDA. Surin is a good example how successful the cooperation with the local health structure can be. Photograph by Stefan Pleger

In November 2006, Thailand announced its first ever decision to issue a compulsory licence for the antiretroviral efavirenz, which was patented and priced out of reach of patients in the country. The move allowed Thailand to import significantly more affordable generic versions of the drug from Indian manufacturers, and subsequently produce the drugs locally. In 2007, Thailand issued two further compulsory licences, for the antiretroviral drug combination lopinavir/ritonavir, which brought the price down by 75%, and for clopidogrel bisulfate, a treatment for cardiovascular disease.

Brazil followed suit in May 2007 with its own compulsory licence for government use on efavirenz. Brazil is also purchasing the generic version from India while it develops local production through government laboratories. Most recently, Ecuador issued a compulsory licence for which halved the cost of the crucial AIDS drug lopinavir/ritonavir for the public health system.

Moves such as these are by no means revolutionary. Indeed, countries both from the industrialised world (such as Italy or the US) and the developing world (including Malaysia or Indonesia) have resorted to compulsory licences in the recent past.

What is perhaps most noteworthy is that the move, although perfectly legal under the TRIPS Agreement, attracted a storm of criticism and retaliatory measures from governments and companies alike. Thailand for example was threatened with trade sanctions by the European Commission and the US – and even the World Health Organization warned Thailand against the move, although the WHO Director General later changed her stance.

The scale of the reaction to what is after all a lawful initiative shows how polarised the fight for access to medicines has become, and to what extent the hard fought flexibilities in international law that safeguard access to medicines must be defended.

Last update July 2011